Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Tarceva and Capecitabine for Pancreatic Cancer
This study is ongoing, but not recruiting participants.
Study NCT00125021. Last updated on December 20, 2007.
Information provided by Dana-Farber Cancer Institute
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pancreatic Cancer
Neoplasm Metastasis
Additional conditions recognized in this trial
Pancreatic Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pancreatic Diseases
Pathologic Processes
Interventions listed in this trial
Capecitabine
OSI-774
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Genentech
Roche Global Development
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Back to top of Main Content